China Clarifies Some Genetic Material Rules But More Regulatory Steps Urged
MNCs See Room For More Progress
China provides some long-awaited clarifications regarding the review and approval of international multi-center clinical trials but some groups are still calling for further steps.
You may also be interested in...
China’s new Five-Year Plan for drug quality aims to address hurdles in clinical study ethics committee review while leaving out other restrictions including genetic material export and substandard clinical sites.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.
Only drugs awarded high points under a government-designated scoring method will benefit most from a new pricing scheme in China. The criteria include the products’ innovativeness in terms of pharmaceutical sciences, the clinical value for patients and clinical evidence from clinical studies.